Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in lymphoma/PTLD compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.66 [0.25, 1.73]
7 studies · 2792 participants
Moderate